EOCN
Eocene Ltd.
Price Chart
Latest Quote
$3.08
-0.07 (-2.22%)
Current Price
| Previous Close | $3.15 |
| Open | $3.06 |
| Day High | $3.11 |
| Day Low | $3.06 |
| Volume | 2,090 |
Stock Information
| Shares Outstanding | 1.07M |
| Total Debt | $129K |
| Cash Equivalents | $11.23M |
| Net Income | $-11.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.29M |
| EPS (TTM) | $-15.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-8.02M |
| Income | $-11.34M |
| Book/sh | $12.72 |
| Cash/sh | $10.51 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 4.11 |
| Current Ratio | 4.16 |
| Debt/Eq | 1.01 |
Returns & Margins
| ROA | -30.19% |
| ROE | -68.21% |
Ownership
| Insider Ownership | 3.04% |
| Institutional Ownership | 1.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.24 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.23 |
| SMA50 | $3.66 |
| SMA200 | $4.64 |
| RSI | 37.88 |
| ATR | 0.2888 |
| Shares Float | 977K |
| Short Float | 0.72% |
| Short Ratio | 0.91 |
| Volatility | 0.66 |
| Rel Volume | 0.28 |
Performance History
| Week | +0.33% |
| Month | -15.15% |
| Quarter | -31.25% |
| 6 Months | -34.63% |
| YTD | -53.22% |
| Year | -72.10% |
| 3 Years | -92.31% |
| 5 Years | -99.92% |
| 10 Years | -99.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $3.08 | 2,100 |
| 2026-10-26 | $3.15 | 3,600 |
| 2026-10-23 | $3.03 | 8,700 |
| 2026-10-22 | $3.08 | 7,100 |
| 2026-10-21 | $3.12 | 7,100 |
| 2026-10-20 | $3.07 | 6,600 |
| 2026-10-19 | $2.85 | 7,800 |
| 2026-10-16 | $2.85 | 11,000 |
| 2026-10-15 | $3.05 | 2,000 |
| 2026-10-14 | $3.01 | 9,800 |
| 2026-10-13 | $3.16 | 9,100 |
| 2026-10-12 | $3.22 | 9,500 |
| 2026-10-09 | $3.54 | 4,700 |
| 2026-10-08 | $3.62 | 14,800 |
| 2026-10-07 | $3.46 | 8,500 |
| 2026-10-06 | $3.36 | 10,200 |
| 2026-10-05 | $3.45 | 7,700 |
| 2026-10-02 | $3.61 | 4,900 |
| 2026-10-01 | $3.40 | 12,600 |
| 2026-09-30 | $3.49 | 2,600 |
| 2026-09-29 | $3.55 | 5,600 |
| 2026-09-28 | $3.63 | 3,900 |
About Eocene Ltd.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
đ° Latest News
No news articles available at the moment. Check back later for updates on EOCN.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,510,000 | $6,278,000 | $7,492,000 | $17,651,000 |
| Rent Expense Supplemental | $34,000 | $117,000 | $261,000 | $401,000 |
| Other Income Expense | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Net Non Operating Interest Income Expense | $819,000 | $-122,000 | $364,000 | $275,000 |
| Total Other Finance Cost | $95,000 | $625,000 | $11,000 | $22,000 |
| Operating Expense | $8,510,000 | $6,278,000 | $7,492,000 | $17,651,000 |
| General And Administrative Expense | $3,636,000 | $3,299,000 | $3,923,000 | $4,656,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Interest Income | $819,000 | $-122,000 | $364,000 | $275,000 |
| Interest Income | $914,000 | $503,000 | $375,000 | $297,000 |
| Normalized Income | $-7,691,000 | $-6,400,000 | $-7,128,000 | $-17,376,000 |
| Net Income From Continuing And Discontinued Operation | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Total Operating Income As Reported | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Net Income Common Stockholders | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income Including Noncontrolling Interests | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income Continuous Operations | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Pretax Income | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Special Income Charges | $-2,461,000 | $-1,145,000 | $0 | $0 |
| Interest Income Non Operating | $914,000 | $503,000 | $375,000 | $297,000 |
| Operating Income | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Per Share | ||||
| Diluted EPS | $-19.12 | $-64.64 | $-240.00 | $-1022.40 |
| Basic EPS | $-19.12 | $-64.64 | $-240.00 | $-1022.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,892,000 | $-5,078,000 | $-7,677,000 | $-17,126,000 |
| Total Unusual Items | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Total Unusual Items Excluding Goodwill | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Reconciled Depreciation | $0 | $83,000 | $31,000 | $35,000 |
| EBITDA (Bullshit earnings) | $-8,510,000 | $-6,195,000 | $-7,461,000 | $-17,616,000 |
| EBIT | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Diluted Average Shares | $538,915 | $116,352 | $28,849 | $17,460 |
| Basic Average Shares | $538,915 | $116,352 | $28,849 | $17,460 |
| Diluted NI Availto Com Stockholders | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Write Off | $2,461,000 | $1,145,000 | $0 | $0 |
| Gain On Sale Of Security | $-157,000 | $28,000 | $216,000 | $-490,000 |
| Research And Development | $4,874,000 | $2,979,000 | $3,569,000 | $12,995,000 |
| Selling General And Administration | $3,636,000 | $3,299,000 | $3,923,000 | $4,656,000 |
| Other Gand A | $899,000 | $896,000 | $908,000 | $1,084,000 |
| Insurance And Claims | $378,000 | $389,000 | $677,000 | $1,094,000 |
| Rent And Landing Fees | $34,000 | $117,000 | $261,000 | $401,000 |
| Salaries And Wages | $2,325,000 | $1,897,000 | $2,077,000 | $2,077,000 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Total Assets | $18,627,000 | $18,500,000 | $16,629,000 | $16,561,000 |
| Total Non Current Assets | $0 | $2,376,000 | $3,390,000 | $1,837,000 |
| Non Current Note Receivables | $0 | $257,000 | $0 | - |
| Current Assets | $18,627,000 | $16,124,000 | $13,239,000 | $14,724,000 |
| Restricted Cash | $124,000 | $121,000 | $117,000 | $114,000 |
| Prepaid Assets | $267,000 | $463,000 | $315,000 | $668,000 |
| Receivables | $80,000 | $209,000 | $165,000 | $157,000 |
| Other Receivables | $80,000 | $209,000 | $165,000 | $157,000 |
| Cash Cash Equivalents And Short Term Investments | $18,156,000 | $15,331,000 | $12,642,000 | $13,785,000 |
| Cash And Cash Equivalents | $3,985,000 | $4,652,000 | $2,861,000 | $2,016,000 |
| Investmentin Financial Assets | - | - | $0 | $1,500,000 |
| Debt | ||||
| Total Debt | - | $0 | $41,000 | $215,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $44,000 |
| Current Debt And Capital Lease Obligation | - | - | $41,000 | $171,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,845,000 | $2,173,000 | $2,750,000 | $3,138,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $44,000 |
| Current Liabilities | $2,845,000 | $2,173,000 | $2,750,000 | $3,094,000 |
| Payables And Accrued Expenses | $2,288,000 | $1,570,000 | $2,138,000 | $2,763,000 |
| Payables | $2,005,000 | $1,314,000 | $1,879,000 | $2,567,000 |
| Other Payable | $2,000 | $6,000 | - | $7,000 |
| Accounts Payable | $2,003,000 | $1,308,000 | $1,879,000 | $2,560,000 |
| Equity | ||||
| Common Stock Equity | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Total Equity Gross Minority Interest | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Stockholders Equity | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Gains Losses Not Affecting Retained Earnings | $-303,000 | $-416,000 | $-454,000 | $-745,000 |
| Other Equity Adjustments | $-303,000 | $-416,000 | $-454,000 | $-745,000 |
| Retained Earnings | $-210,778,000 | $-200,469,000 | $-192,952,000 | $-186,040,000 |
| Long Term Equity Investment | $0 | $2,119,000 | $3,265,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $822,673 | $208,110 | $52,555 | $17,502 |
| Share Issued | $822,673 | $208,110 | $52,555 | $17,502 |
| Tangible Book Value | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Invested Capital | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Working Capital | $15,782,000 | $13,951,000 | $10,489,000 | $11,630,000 |
| Total Capitalization | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Additional Paid In Capital | $223,455,000 | $216,470,000 | $207,076,000 | $200,138,000 |
| Capital Stock | $3,408,000 | $742,000 | $209,000 | $70,000 |
| Common Stock | $3,408,000 | $742,000 | $209,000 | $70,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $557,000 | $603,000 | $571,000 | $160,000 |
| Current Accrued Expenses | $283,000 | $256,000 | $259,000 | $196,000 |
| Investments And Advances | $0 | $2,119,000 | $3,265,000 | $1,500,000 |
| Investmentsin Associatesat Cost | $0 | $2,119,000 | $3,265,000 | $0 |
| Other Short Term Investments | $14,171,000 | $10,679,000 | $9,781,000 | $11,769,000 |
| Capital Lease Obligations | - | $0 | $41,000 | $215,000 |
| Current Capital Lease Obligation | - | $0 | $41,000 | $171,000 |
| Net PPE | - | $0 | $125,000 | $337,000 |
| Accumulated Depreciation | - | $-1,103,000 | $-1,019,000 | $-988,000 |
| Gross PPE | - | $1,103,000 | $1,144,000 | $1,325,000 |
| Leases | - | $236,000 | $235,000 | $235,000 |
| Other Properties | - | $737,000 | $779,000 | $960,000 |
| Machinery Furniture Equipment | - | $130,000 | $130,000 | $130,000 |
| Properties | - | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | - | $0 | $44,000 |
| Available For Sale Securities | - | - | - | $1,500,000 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,505,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,501,000 |
| Cash Flow From Continuing Operating Activities | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,501,000 |
| Operating Gains Losses | $81,000 | $12,000 | $13,000 | $523,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-3,375,000 | $-1,111,000 | $800,000 | $17,563,000 |
| Cash Flow From Continuing Investing Activities | $-3,375,000 | $-1,111,000 | $800,000 | $17,563,000 |
| Net Other Investing Changes | - | $-250,000 | - | - |
| Capital Expenditure | - | - | - | $-4,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Financing Cash Flow | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Cash Flow From Continuing Financing Activities | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Net Common Stock Issuance | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Common Stock Issuance | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Other | ||||
| End Cash Position | $4,109,000 | $4,773,000 | $2,978,000 | $2,130,000 |
| Beginning Cash Position | $4,773,000 | $2,978,000 | $2,130,000 | $2,998,000 |
| Changes In Cash | $-664,000 | $1,795,000 | $848,000 | $-868,000 |
| Net Investment Purchase And Sale | $-3,375,000 | $-861,000 | $2,300,000 | $17,567,000 |
| Sale Of Investment | $1,611,000 | $5,504,000 | $8,633,000 | $21,440,000 |
| Purchase Of Investment | $-4,986,000 | $-6,365,000 | $-6,333,000 | $-3,873,000 |
| Net Business Purchase And Sale | $0 | $0 | $-1,500,000 | $0 |
| Purchase Of Business | $0 | $0 | $-1,500,000 | $0 |
| Change In Working Capital | $912,000 | $-728,000 | $132,000 | $-2,451,000 |
| Change In Payables And Accrued Expense | $672,000 | $-536,000 | $-213,000 | $-2,751,000 |
| Change In Payable | $672,000 | $-536,000 | $-213,000 | $-2,751,000 |
| Change In Account Payable | $695,000 | $-571,000 | $-681,000 | $-2,311,000 |
| Change In Receivables | $240,000 | $-192,000 | $345,000 | $300,000 |
| Other Non Cash Items | $-21,000 | $611,000 | $-47,000 | $-36,000 |
| Stock Based Compensation | $546,000 | $531,000 | $892,000 | $1,296,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $-265,000 | $0 |
| Asset Impairment Charge | $2,461,000 | $1,145,000 | $0 | $0 |
| Amortization Of Securities | $15,000 | $-17,000 | $19,000 | $-2,000 |
| Depreciation Amortization Depletion | $0 | $83,000 | $31,000 | $35,000 |
| Depreciation And Amortization | $0 | $83,000 | $31,000 | $35,000 |
| Depreciation | $0 | $83,000 | $31,000 | $35,000 |
| Gain Loss On Investment Securities | $81,000 | $12,000 | $13,000 | $523,000 |
| Net Income From Continuing Operations | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net PPE Purchase And Sale | - | $0 | $0 | $-4,000 |
| Purchase Of PPE | - | $0 | $0 | $-4,000 |
| Change In Other Working Capital | - | $7,000 | $-53,000 | - |
| Earnings Losses From Equity Investments | - | $-7,000 | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
Fetched: 2026-10-26